In addition to pharmaceutical and biopharmaceutical sponsors outsourcing
clinical trials to Contract Research Organizations (CROs) to gain flexibility and speed the drug development process, key factors impacting market trends include technology and digital modernization of clinical trials, advanced therapies and protocol design complexity, and the transition to decentralized trials resulting from the pandemic. Each of these trends harbor inherent complexities, driving an increased reliance on CROs to help improve efficiency and productivity.
Serge Bodart, Chief Commercial Officer at IDDI Group discusses key market trends and opportunities, today’s complex trials, and the post-pandemic outlook for clinical development.
Kristin Brooks, Managing Editor, Contract Pharma 05.25.21